Head to Head Contrast: Acutus Medical (NASDAQ:AFIB) and Orchestra BioMed (NASDAQ:OBIO)

Orchestra BioMed (NASDAQ:OBIO) and Acutus Medical (NASDAQ:AFIB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Orchestra BioMed and Acutus Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	0	0	4	0	3.00
Acutus Medical	0	0	0	0	0.00

Orchestra BioMed presently has a consensus target price of $15.75, indicating a potential upside of 204.64%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than Acutus Medical.

Profitability

This table compares Orchestra BioMed and Acutus Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-2,179.33%	-107.04%	-70.88%
Acutus Medical	-272.74%	-311.64%	-11.57%

Valuation & Earnings

This table compares Orchestra BioMed and Acutus Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$2.65 million	74.25	-$49.12 million	($1.61)	-3.21
Acutus Medical	$7.16 million	0.25	-$81.66 million	N/A	N/A

Orchestra BioMed has higher earnings, but lower revenue than Acutus Medical.

Insider and Institutional Ownership

53.5% of Orchestra BioMed shares are held by institutional investors. Comparatively, 56.9% of Acutus Medical shares are held by institutional investors. 6.7% of Orchestra BioMed shares are held by company insiders. Comparatively, 5.2% of Acutus Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Orchestra BioMed beats Acutus Medical on 7 of the 11 factors compared between the two stocks.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

About Acutus Medical

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.